Clinical trial
N2001-03: CEP-701 in Treating Young Patients With Recurrent or Refractory…
NCT00084422 · New Approaches to Neuroblastoma Therapy Consortium, Other · Completed
Key facts
| NCT number | NCT00084422 |
|---|---|
| Title | N2001-03: CEP-701 in Treating Young Patients With Recurrent or Refractory High-Risk Neuroblastoma |
| Official title | A Phase I Study Of CEP-701 In Patients With Refractory Neuroblastoma (IND # 67,722) |
| Lead sponsor | New Approaches to Neuroblastoma Therapy Consortium, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Neuroblastoma |
| Intervention type | Drug |
| Interventions | lestaurtinib |
| Enrollment | 47 |
| Start date | Aug 1, 2003 |
| Primary completion | Sep 1, 2009 |
| Completion | Feb 1, 2011 |
| First posted | Jun 11, 2004 |
| Last update posted | Apr 10, 2023 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: